Pacira Pharma +2% on Q4 beat

|About: Pacira BioSciences, Inc. (PCRX)|By:, SA News Editor

Pacira Pharmaceuticals (PCRX) Q4 results: Revenues: $95.1M (+20.2%); EXPAREL: $94.4M (+19.9%); Other product sales: $0.3M (+50.0%); Royalty revenue: $0.4M (+100.0%).

Net Income: $8.3M (+80.4%); Non-GAAP Net Income: $19.8M (+23.8%); EPS: $0.20 (+81.8%); Non-GAAP EPS: $0.47 (+23.7%); Quick Assets: $383.5M (+23.2%).

2019 Guidance: EXPAREL net product sales: $400M - 410M.

The consensus Revenue and non-GAAP EPS estimate was $93.71M and $0.27, respectively.

Shares are up 2% premarket.

Previously: Pacira Pharmaceuticals beats by $0.20, beats on revenue (Feb. 28)

Subscribe for full text news in your inbox